LORI LEE: Open Payments
NPI 1346642394 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,957 in 118 payments from 14 companies in 2025. Trend: 2023 $1,934 · 2024 $3,081 · 2025 $1,957
Food & beverage: $1,957
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 15 | $360 |
| Phathom Pharmaceuticals, Inc. | 12 | $261 |
| ABBVIE INC. | 22 | $234 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $175 |
| Janssen Biotech, Inc. | 17 | $160 |
| Lilly USA, LLC | 9 | $158 |
| Celltrion USA Inc. | 6 | $127 |
| Gilead Sciences, Inc. | 5 | $91 |
| QOL Medical, LLC | 2 | $50 |
Products named: REZDIFFRA, VOQUEZNA, XIFAXAN, TREMFYA, OMVOH, VEGZELMA, RINVOQ, EOHILIA.
Industry payments across TX — which companies pay providers there.
